This is the authors' abstract. We don't add key points for this paper.
Background Master protocols, classified as basket trials, umbrella trials, and platform trials, are a novel approach that offers enhanced efficiency and a more ethical approach to trial evaluation. Despite the many advantages of these designs, they are infrequently used. Methods We conducted a landscape analysis of published master protocols using a systematic literature search to determine what trials have been conducted, with an overall goal of improving literacy in this emerging concept. English-language studies identified from MEDLINE, EMBASE, and CENTRAL databases and hand-searches of published reviews and registries from inception to October 1st, 2018 Results We identified 59 master protocols (35 basket-, 13 umbrella-, 11 platform trials). The number of master protocols has increased rapidly over the last five years. Most have been conducted in the US (n=32/59) and investigated experimental drugs (n=58/59), in the field of oncology (n=53/59). The majority of basket trials were exploratory (i.e. phase I/II; n=33/35) and not randomized (n=30/35), with half only investigating a single intervention. The median sample size of basket trials was 208 participants (Interquartile range, Q3-Q1 [IQR]: 589-92), with a median study duration of 60.9 (IQR: 71.9-39.9) months. Similar to basket trials, most of umbrella trials were exploratory (n=11/13), but use of randomization was more common (n=8/13). The median sample size of umbrella trials was 342 participants (IQR: 400-250), with a median study duration of 62.9 (IQR: 82.8-46.9) months. The median number of interventions investigated in umbrella trials was 5 (IQR: 5-4). In platform trials, randomization (n=10/11) and phase III investigation (n=5/10; one did not report information on phase), with four of them using seamless II/III design, were more common. The median sample size was 783.5 (IQR: 1857.5-319.5), with median study duration of 63.3 (IQR: 115.0-41.9) months. Conclusions We anticipate that the number of master protocols will continue to increase at a rapid pace over the upcoming decades. More efforts to improve awareness and training are needed to apply these innovative trial design methods to fields outside of oncology.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mills et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: